ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Botox Penile Injections for Erectile Dysfunction
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 208470" data-attributes="member: 13851"><p><em><strong>*Approximately four out of five patients with ED are attributed to <u>organic etiologies</u> with multiple signal transduction pathways converge to <u>endothelial dysfunction</u>.9 Thus, effective therapy of vasculogenic ED should be directed toward this factor</strong></em></p><p><em><strong></strong></em></p><p><em><strong>*Onabotulinum toxin-A (BTX) is widely used for the treatment of various medical conditions.8,10 BTX exerts multiple pharmacological effects, which may qualify BTX as a therapeutic candidate for the treatment of ED. For instance, it blocks the release of acetylcholine and norepinephrine-mediated sympathetic pathway and increases the expression of vascular endothelial growth factor and CD31.11 The expression of these factors and the activation of its downstream signaling cascades enhance vasodilation and endothelial cell proliferation and thus are involved in the pathophysiology of ED. These findings represent the theoretical and molecular rationale for the potential effects of BTX in the treatment of vasculogenic ED </strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 208470, member: 13851"] [I][B]*Approximately four out of five patients with ED are attributed to [U]organic etiologies[/U] with multiple signal transduction pathways converge to [U]endothelial dysfunction[/U].9 Thus, effective therapy of vasculogenic ED should be directed toward this factor *Onabotulinum toxin-A (BTX) is widely used for the treatment of various medical conditions.8,10 BTX exerts multiple pharmacological effects, which may qualify BTX as a therapeutic candidate for the treatment of ED. For instance, it blocks the release of acetylcholine and norepinephrine-mediated sympathetic pathway and increases the expression of vascular endothelial growth factor and CD31.11 The expression of these factors and the activation of its downstream signaling cascades enhance vasodilation and endothelial cell proliferation and thus are involved in the pathophysiology of ED. These findings represent the theoretical and molecular rationale for the potential effects of BTX in the treatment of vasculogenic ED [/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Botox Penile Injections for Erectile Dysfunction
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top